Señalización JAK / STAT
Los inhibidores de la señalización JAK/STAT son compuestos que interrumpen la vía de la cinasa Janus (JAK) y del transductor y activador de la transcripción (STAT), la cual está involucrada en la señalización de citoquinas, el crecimiento celular y la respuesta inmunitaria. Estos inhibidores son herramientas importantes para estudiar la regulación de esta vía y su papel en diversas enfermedades, como el cáncer, los trastornos inmunitarios y las condiciones inflamatorias. Los inhibidores de JAK/STAT también están siendo desarrollados como terapias dirigidas para estas enfermedades. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de la señalización JAK/STAT para apoyar su investigación en biología molecular, oncología e inmunología.
Subcategorías de "Señalización JAK / STAT"
Productos de "Señalización JAK / STAT"
Ordenar por
Pim-1 kinase inhibitor 8
CAS:Pim-1 kinase inhibitor 8 is a Pim-1 kinase inhibitor with anticancer activity that inhibits cell migration and can be studied in breast cancer.Fórmula:C14H17N3O3Pureza:99.81%Forma y color:SoildPeso molecular:275.3Golidocitinib
CAS:Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).Fórmula:C25H31N9O2Pureza:100% - 98.87%Forma y color:SolidPeso molecular:489.57Ref: TM-T10431
2mg96,00€5mg163,00€10mg268,00€25mg465,00€50mg618,00€100mg880,00€1mL*10mM (DMSO)170,00€Baricitinib phosphate
CAS:Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.Fórmula:C16H20N7O6PSPureza:98.87% - 99.68%Forma y color:SolidPeso molecular:469.41Ritlecitinib
CAS:Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.Fórmula:C15H19N5OPureza:98.82% - 99.92%Forma y color:SolidPeso molecular:285.34Ref: TM-T5382
2mg47,00€5mg70,00€10mg111,00€25mg216,00€50mg329,00€100mg495,00€200mg705,00€500mg1.064,00€1mL*10mM (DMSO)77,00€Cucurbitacin I
CAS:Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.Fórmula:C30H42O7Pureza:96.69% - 98.2%Forma y color:SolidPeso molecular:514.65ZM39923 hydrochloride
CAS:ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.Fórmula:C23H25NO·HClPureza:98.05%Forma y color:SolidPeso molecular:367.91YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65Itacitinib
CAS:Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.Fórmula:C26H23F4N9OPureza:96.4% - 99.01%Forma y color:SolidPeso molecular:553.51Ref: TM-T3998
1mg49,00€2mg71,00€5mg111,00€10mg180,00€25mg325,00€50mg543,00€100mg780,00€500mg1.549,00€1mL*10mM (DMSO)137,00€WHI-P97
CAS:WHI-P97 is a rationally designed potent inhibitor of JAK-3.Fórmula:C16H13Br2N3O3Pureza:99.93%Forma y color:SolidPeso molecular:455.1Ilginatinib maleate
CAS:Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C25H24FN7O4Pureza:99.74% - 99.82%Forma y color:SolidPeso molecular:505.5Ref: TM-T12266L
1mg64,00€5mg138,00€10mg187,00€25mg273,00€50mg393,00€100mg562,00€200mg743,00€1mL*10mM (DMSO)153,00€SMI-16a
CAS:SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (Fórmula:C13H13NO3SPureza:99.99%Forma y color:SolidPeso molecular:263.31Ref: TM-T3989
1mg35,00€2mg48,00€5mg70,00€10mg87,00€25mg160,00€50mg235,00€100mg354,00€1mL*10mM (DMSO)92,00€FM-381
CAS:FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.Fórmula:C24H24N6O2Pureza:98.44%Forma y color:SolidPeso molecular:428.49Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39Ref: TM-T78207
1mg52,00€5mg116,00€10mg178,00€25mg359,00€50mg533,00€100mg750,00€200mg1.064,00€1mL*10mM (DMSO)127,00€WDR5-0103 hydrochloride[890190-22-4(free base)]
WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:Fórmula:C21H26ClN3O4Pureza:99.66%Forma y color:SolidPeso molecular:419.9JAK1-IN-16
JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.Fórmula:C20H15ClF3N3OSForma y color:SolidPeso molecular:437.87Gusacitinib
CAS:Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).Fórmula:C24H28N8O2Pureza:98.06% - 99.94%Forma y color:SolidPeso molecular:460.53Ref: TM-T14331
1mg42,00€5mg88,00€10mg123,00€25mg188,00€50mg350,00€100mg522,00€200mg750,00€1mL*10mM (DMSO)116,00€(E/Z)-Zotiraciclib
CAS:(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.Fórmula:C23H24N4OPureza:97% - 98.03%Forma y color:SolidPeso molecular:372.46Ref: TM-T21503
1mg46,00€2mg59,00€5mg87,00€10mg119,00€25mg210,00€50mg349,00€100mg507,00€1mL*10mM (DMSO)96,00€Momelotinib sulfate
CAS:Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Fórmula:C23H26N6O10S2Pureza:98%Forma y color:SolidPeso molecular:610.62JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46JAK/HDAC-IN-4
JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.Fórmula:C30H32N8O5SForma y color:SolidPeso molecular:616.69JAK3i
CAS:JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.Fórmula:C18H15FN4O3Pureza:98.61% - 99.81%Forma y color:SolidPeso molecular:354.34PIM-1 Inhibitor 2
CAS:PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.Fórmula:C17H11ClN4OPureza:98.81%Forma y color:SolidPeso molecular:322.75Solcitinib
CAS:Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.Fórmula:C22H23N5O2Pureza:99.61% - 99.82%Forma y color:SolidPeso molecular:389.45TCS-PIM-1-4a
CAS:SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).Fórmula:C11H6F3NO2SPureza:99.89%Forma y color:SolidPeso molecular:273.23JAK-IN-29
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].Fórmula:C17H14ClN5O2Pureza:98%Forma y color:SolidPeso molecular:355.78JAK3/BTK-IN-1
CAS:JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two importantFórmula:C25H28N8OPureza:97.89%Forma y color:SolidPeso molecular:456.54Ruxolitinib phosphate
CAS:Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.Fórmula:C17H21N6O4PPureza:100% - 99.91%Forma y color:SolidPeso molecular:404.36Ref: TM-T3043
1g615,00€5mg52,00€10mg65,00€25mg82,00€50mg97,00€100mg145,00€200mg227,00€500mg418,00€1mL*10mM (DMSO)59,00€PIM1-IN-4
CAS:PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.Fórmula:C27H25BrCl2CuN6OPureza:98%Forma y color:SolidPeso molecular:663.88Deucravacitinib
CAS:Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.Fórmula:C20H19D3N8O3Pureza:100% - 99.43%Forma y color:SolidPeso molecular:425.46Ref: TM-T14687
1mg70,00€5mg153,00€10mg274,00€25mg432,00€50mg638,00€100mg908,00€200mg1.225,00€500mg1.825,00€1mL*10mM (DMSO)166,00€GDC-0214
CAS:GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).Fórmula:C28H28ClF2N9O3Pureza:98.54%Forma y color:SolidPeso molecular:612.03Ref: TM-T9826
1mg87,00€5mg192,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.159,00€1mL*10mM (DMSO)259,00€AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Fórmula:C29H28F3N5O2Pureza:98%Forma y color:SolidPeso molecular:535.56JAK2-IN-4
CAS:JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.Fórmula:C23H27N5O4SPureza:98%Forma y color:SolidPeso molecular:469.56JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Fórmula:C26H30ClN7O2Forma y color:SolidPeso molecular:508.02Ruxolitinib
CAS:Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.Fórmula:C17H18N6Pureza:100% - 99.99%Forma y color:SolidPeso molecular:306.36Ref: TM-T1829
5mg58,00€10mg74,00€25mg92,00€50mg116,00€100mg155,00€200mg245,00€500mg414,00€1mL*10mM (DMSO)65,00€NVP-BSK805
CAS:NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.Fórmula:C27H28F2N6OPureza:98%Forma y color:SolidPeso molecular:490.55SHR0302
CAS:SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,Fórmula:C18H22N8O2SPureza:99.11%Forma y color:SolidPeso molecular:414.48Ref: TM-T9195
1mg160,00€5mg393,00€10mg620,00€25mg1.035,00€50mg1.483,00€100mg1.882,00€1mL*10mM (DMSO)455,00€lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Fórmula:C16H25N5OSForma y color:SolidPeso molecular:335.468Antitumor agent-195
Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.Fórmula:C22H22N2O4Forma y color:SolidPeso molecular:378.42AZD1208
CAS:AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.Fórmula:C21H21N3O2SPureza:97.24% - 99.83%Forma y color:SolidPeso molecular:379.48Ref: TM-T2300
2mg38,00€5mg51,00€10mg74,00€25mg118,00€50mg213,00€100mg378,00€200mg495,00€500mg792,00€1mL*10mM (DMSO)57,00€JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nMFórmula:C20H21F2N7OPureza:98%Forma y color:SolidPeso molecular:413.42JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Fórmula:C31H31F3N8O4Forma y color:SolidPeso molecular:639.64QL-1200186
CAS:QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production followingFórmula:C26H27N7O3Pureza:98%Forma y color:SolidPeso molecular:485.54Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Fórmula:C27H36N6O3SPureza:98.23% - 99.96%Forma y color:SolidPeso molecular:524.68Ref: TM-T1995
1g625,00€5mg49,00€10mg69,00€50mg113,00€100mg134,00€200mg216,00€500mg472,00€1mL*10mM (DMSO)57,00€Pyridone 6
CAS:Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Fórmula:C18H16FN3OPureza:97.10% - 98.74%Forma y color:SolidPeso molecular:309.34Ref: TM-T3080
1mg82,00€2mg106,00€5mg162,00€10mg221,00€25mg449,00€50mg658,00€100mg939,00€500mg1.882,00€1mL*10mM (DMSO)177,00€Baricitinib
CAS:Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Fórmula:C16H17N7O2SPureza:100% - 99.79%Forma y color:SolidPeso molecular:371.42Ref: TM-T2485
5mg50,00€10mg73,00€25mg90,00€50mg115,00€100mg144,00€200mg188,00€500mg311,00€1mL*10mM (DMSO)69,00€Filgotinib
CAS:Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Forma y color:SolidPeso molecular:425.5JAK2 Inhibitor V
CAS:JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.Fórmula:C23H24N2OPureza:96.69% - 99.15%Forma y color:SolidPeso molecular:344.45Ref: TM-T3042
2mg39,00€5mg57,00€10mg85,00€25mg157,00€50mg274,00€100mg505,00€500mg1.121,00€1mL*10mM (DMSO)63,00€DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstratingFórmula:C36H40Cl2N2O10PtPureza:98%Forma y color:SolidPeso molecular:926.7AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H14FN5OForma y color:SolidPeso molecular:323.32TCS 21311
CAS:TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Fórmula:C27H25F3N4O4Pureza:≥98%Forma y color:SolidPeso molecular:526.51AZ960
CAS:AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).Fórmula:C18H16F2N6Pureza:96.02% - 98.51%Forma y color:SolidPeso molecular:354.36Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Fórmula:C17H18N6Pureza:99.37% - 99.79%Forma y color:SolidPeso molecular:306.36GNE-955
CAS:GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).Fórmula:C22H24N8OPureza:98%Forma y color:SolidPeso molecular:416.48M-110
CAS:M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).Fórmula:C22H28ClN5O3Pureza:98.30%Forma y color:SolidPeso molecular:445.94AG490
CAS:AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Forma y color:Yellow SolidPeso molecular:294.3JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Fórmula:C18H20N4O3Pureza:98.04% - 98.19%Forma y color:SolidPeso molecular:340.38Ref: TM-T11704
1mg133,00€2mg188,00€5mg321,00€10mg518,00€25mg1.035,00€50mg1.644,00€100mg2.680,00€200mg3.591,00€1mL*10mM (DMSO)354,00€JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Fórmula:C23H22FN5O4SPureza:99.57%Forma y color:SolidPeso molecular:483.52Momelotinib Mesylate
CAS:Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Fórmula:C24H26N6O5SPureza:98%Forma y color:SolidPeso molecular:510.57Tofacitinib
CAS:Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.Fórmula:C16H20N6OPureza:100% - 99.71%Forma y color:SolidPeso molecular:312.37JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Fórmula:C18H18N4Forma y color:SolidPeso molecular:290.36LFM-A13
CAS:LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR,Fórmula:C11H8Br2N2O2Pureza:99.9%Forma y color:SolidPeso molecular:360AZD-1897
CAS:AZD-1897 is a highly efficient ATP-competitive pan-PIM inhibitor with anti-cancer and anti-leukemia activity, used in multiple myeloma research.Fórmula:C18H23N3O3SPureza:99.49%Forma y color:SolidPeso molecular:361.46AZD-1480
CAS:AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.Fórmula:C14H14ClFN8Pureza:97.5% - 98.55%Forma y color:SolidPeso molecular:348.77TG101209
CAS:TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.Fórmula:C26H35N7O2SPureza:100% - 99.36%Forma y color:SolidPeso molecular:509.67Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Fórmula:C24H25N7O2Forma y color:SolidPeso molecular:443.50Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Fórmula:C18H21F2N7OPureza:99.8%Forma y color:SolidPeso molecular:389.4Ref: TM-TQ0010
1mg35,00€5mg74,00€10mg110,00€25mg226,00€50mg411,00€100mg660,00€200mg917,00€1mL*10mM (DMSO)81,00€RO8191
CAS:RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.Fórmula:C14H5F6N5OPureza:98.85% - ≥98%Forma y color:SolidPeso molecular:373.21MM-589 TFA
CAS:MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C30H45F3N8O7Pureza:98%Forma y color:SolidPeso molecular:686.72Atractylenolide I
CAS:Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.Fórmula:C15H18O2Pureza:97.55% - 99.83%Forma y color:SolidPeso molecular:230.3JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Fórmula:C26H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:521.59AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H13ClFN5OForma y color:SolidPeso molecular:357.77WDR5-IN-6
CAS:WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6Fórmula:C13H8Cl2N2O2SPureza:99.69%Forma y color:SoildPeso molecular:327.19JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Fórmula:C21H19N7O2S2Pureza:98%Forma y color:SolidPeso molecular:465.55Protosappanin A
CAS:Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.Fórmula:C15H12O5Pureza:100% - 99.42%Forma y color:SolidPeso molecular:272.25Ref: TM-TJS1779
1mg87,00€5mg216,00€10mg354,00€25mg582,00€50mg825,00€100mg1.111,00€1mL*10mM (DMSO)197,00€Momelotinib
CAS:Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.Fórmula:C23H22N6O2Pureza:97.47% - 99.56%Forma y color:SolidPeso molecular:414.46Ref: TM-T1849
1mg38,00€2mg49,00€5mg81,00€10mg95,00€25mg166,00€50mg259,00€100mg406,00€200mg625,00€1mL*10mM (DMSO)88,00€JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.Fórmula:C20H24N6O2SPureza:98%Forma y color:SolidPeso molecular:412.51JAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,Fórmula:C27H26N6OPureza:98%Forma y color:SolidPeso molecular:450.53BD750
CAS:BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM inFórmula:C14H13N3OSPureza:99.02%Forma y color:SolidPeso molecular:271.34GLPG0634 analog
CAS:GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.Fórmula:C23H18N6O2Pureza:100% - 99.22%Forma y color:SolidPeso molecular:410.43Ref: TM-T3076
1mg40,00€2mg52,00€5mg88,00€10mg144,00€25mg264,00€50mg465,00€100mg658,00€500mg1.378,00€1mL*10mM (DMSO)87,00€Fedratinib hydrochloride hydrate
CAS:Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.46%Forma y color:SolidPeso molecular:615.61XL019
CAS:XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.Fórmula:C25H28N6O2Pureza:99.19%Forma y color:SolidPeso molecular:444.53SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Fórmula:C15H8Cl2FN3OPureza:99.56%Forma y color:SolidPeso molecular:336.15Ref: TM-T8719
1mg46,00€5mg93,00€10mg140,00€25mg240,00€50mg363,00€100mg452,00€200mg630,00€1mL*10mM (DMSO)99,00€SAR-20347
CAS:SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).Fórmula:C21H18ClFN4O4Pureza:99.35% - 99.77%Forma y color:SolidPeso molecular:444.84Ref: TM-T4210
1mg35,00€5mg80,00€10mg116,00€25mg227,00€50mg354,00€100mg588,00€200mg818,00€1mL*10mM (DMSO)88,00€BMS-911543
CAS:BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.Fórmula:C23H28N8OPureza:97.69% - 99.98%Forma y color:SolidPeso molecular:432.52Delgocitinib
CAS:Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Fórmula:C16H18N6OPureza:99.90%Forma y color:SolidPeso molecular:310.35Ref: TM-T15096
1mg169,00€5mg311,00€10mg487,00€25mg929,00€50mg1.415,00€100mg2.062,00€200mg2.775,00€1mL*10mM (DMSO)349,00€Hispidulin
CAS:Hispidulin, a natural flavone with a broad spectrum of biological activities, is a Pim-1 inhibitor (IC50: 2.71 μM).Fórmula:C16H12O6Pureza:97.54% - 98.53%Forma y color:SolidPeso molecular:300.26CHZ868
CAS:CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.Fórmula:C22H19F2N5O2Pureza:99.38%Forma y color:SolidPeso molecular:423.42Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Fórmula:C20H20N4O2SForma y color:SolidPeso molecular:380.463Ilginatinib
CAS:Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H20FN7Pureza:98.40% - 99.01%Forma y color:SolidPeso molecular:389.43Ref: TM-T12266
1mg64,00€5mg138,00€10mg187,00€25mg273,00€50mg393,00€100mg562,00€200mg743,00€1mL*10mM (DMSO)133,00€HJ-PI01
CAS:HJ-PI01 (HJ-PI01) is a Pim-2 inhibitor. HJ-PI01 (HJ-PI01) induces apoptosis and autophagic cell death in triple-negative human breast cancer.Fórmula:C14H11NO2Pureza:99.55%Forma y color:SolidPeso molecular:225.24Ref: TM-T9583
1mg35,00€5mg80,00€10mg116,00€25mg259,00€50mg383,00€100mg545,00€200mg740,00€1mL*10mM (DMSO)77,00€JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].Fórmula:C15H17N7Pureza:98%Forma y color:SolidPeso molecular:295.34JANEX-1
CAS:JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.Fórmula:C16H15N3O3Pureza:98% - 99.73%Forma y color:SolidPeso molecular:297.31Ref: TM-T2045
1mg44,00€2mg55,00€5mg92,00€10mg150,00€25mg248,00€50mg444,00€100mg652,00€500mg1.378,00€1mL*10mM (DMSO)92,00€MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C28H44N8O5Pureza:98%Forma y color:SolidPeso molecular:572.70Povorcitinib phosphate
CAS:Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.Fórmula:C23H25F5N7O5PPureza:97.71%Forma y color:SolidPeso molecular:605.45Ref: TM-T39113L
1mg65,00€2mg95,00€5mg145,00€10mg212,00€25mg359,00€50mg512,00€100mg695,00€200mg937,00€JAK-IN-33
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].Pureza:98%Forma y color:Odour SolidPeficitinib
CAS:Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Forma y color:SolidPeso molecular:326.39Ref: TM-T6933
2mg40,00€5mg66,00€10mg104,00€25mg182,00€50mg283,00€100mg439,00€200mg645,00€1mL*10mM (DMSO)73,00€FLLL32
CAS:FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Fórmula:C28H32O6Pureza:96.39% - 97.90%Forma y color:SolidPeso molecular:464.55Ref: TM-T6838
2mg46,00€5mg66,00€10mg93,00€25mg124,00€50mg197,00€100mg350,00€500mg840,00€1mL*10mM (DMSO)72,00€Cerdulatinib hydrochloride
CAS:Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.Fórmula:C20H28ClN7O3SPureza:99.23%Forma y color:SolidPeso molecular:482
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
